25D-NBOMe

25D-NBOMe

25D-NBOMe

Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.

Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.

Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Practice Harm Reduction. Proceed with Caution.

Description

25D-NBOMe

Also known as:

  • 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamin[German][ACD/IUPAC Name]
  • 2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine[ACD/IUPAC Name]
  • 2-(2,5-Diméthoxy-4-méthylphényl)-N-(2-méthoxybenzyl)éthanamine[French][ACD/IUPAC Name]
  • 7RET11HE13
  • Benzeneethanamine, 2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-4-methyl-[ACD/Index Name]
  • NBOMe-2C-D
  • 2-(2,5-dimethoxy-4-methylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
  • UNII:7RET11HE13

Uncommon analogue of 2C-D. Extremely potent psychedelic with stimulating qualities. Could cause dangerous vasoconstriction at high doses. May induce uncomfortable body load.

Summary

25D-NBOMe produces an array of primarily visual and stimulating psychedelic effects when administered. The name 25D-NBOMe, which short-hand for 2C-D-NBOMe, is a derivative of the phenethylamine psychedelic 2C-D. It was first synthesized in 2011 by Martin Hansen and subsequently had its activity explored in 2012 and 2014, where it was established to be a potent agonist at the 5-HT2A receptor that produces effects similar to other members of the 25x-NBOMe series.

It is worth noting that compounds of the NBOMe family are not orally active and should be administered sublingually by placing and letting it absorb into one’s mouth over a period of 15-25 minutes. 25D-NBOMe can also be vaporized and inhaled to cause significantly more rapid and powerful effects as well as a shorter duration. However, this route of administration is highly advised against due to the difficulties of measuring and handling substances that are both active in the microgram range as well as having a low therapeutic index.

25D-NBOMe has no history of human use prior to being sold online as a designer drug in 2010. Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25D-NBOMe in humans, and its closely related analogs like 25I-NBOMe has been associated with many deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely.

Therefore it is highly advised to approach this poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices when using it.

History

Chemistry

25D-NBOMe

25D-NBOMe

25D-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as a methyl group attached to carbon R4.

It differs from 2C-D structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right.

25D-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family.

This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Common Name25D-NBOMe
Systematic name25D-NBOMe
FormulaC_{19}H_{25}NO_{3}
SMILESCc1cc(c(cc1OC)CCNCc2ccccc2OC)OC
Std. InChiInChI=1S/C19H25NO3/c1-14-11-19(23-4)15(12-18(14)22-3)9-10-20-13-16-7-5-6-8-17(16)21-2/h5-8,11-12,20H,9-10,13H2,1-4H3
Std. InChiKeyUTVHBNXCFSATDB-UHFFFAOYSA-N
Avg. Mass315.4067 Da
Molecular Weight315.4067
Monoisotopic Mass315.183441 Da
Nominal Mass315
ChemSpider ID48059920

Subscribe for the latest updates

Dosing Guide

Sublingual
Threshold100-300ug.
Light300-500ug.
Common500-1000ug
Strong1000-1250ug+

Duration

25D-NBOMe Duration Data
Onset20-40 minutes
Duration4-6 hours
After-effects6-24 hours

Interactions and Synergies

There are no existing interaction or synergy data for this drug.

General Information

Experiences
Oral
Vaporization
Come up
Dosage
EffectsEuphoria, empathy, insight, brightened colour, Closed/Open eye visuals, enhanced tactile sensation, mental/physical stimulation, decreased appetite, pupil dilation, restlessness, change in perception, ego softening, sweating/chills, muscle tension, confusion, insomnia.
After Effects
Avoid
Warning
Risks
Test Kits
Marguis Test Result
Tolerance
Detection
Half-life
Advice
Note
Note 2:
Note 3:

Effects

Pharmacological Effects

25D-NBOMe has efficacy at the 5-HT2A receptor where it acts as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive. The addition of the NBOMe group to the structure results in a sixteen-fold increase in potency when compared to 2C-D, allowing even the most extreme of doses to fit in liquid form onto tabs and blotter paper, which people often mistake for LSD.

Subjective Effects

{Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Physical Effects

The physical effects of 25D-NBOMe can be broken down into several components which progressively intensify proportional to dosage. These are described below and generally include:

Psychological Effects

The cognitive effects of 25D-NBOMe are remarkably light and underwhelming in comparison to more traditional psychedelics. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout moderate to high doses. At heavy doses, however, mild cognitive alterations become present; this dose seems to be lower in proportion to physical effects when compared to 25I-NBOMe. The most prominent of these cognitive effects generally include:

Visual Effects

Enhancements

25D-NBOMe presents a mild array of possible visual enhancements which generally includes:

Distortions

The visual distortions and alterations which are experienced are detailed below:

Geometry

The visual geometry that is present throughout this trip is often described as very similar in appearance to that of DOM. It can be comprehensively described as smooth and organic in style, simple in complexity, fine and zoomed out in detail, slow and fluid in motion, structured in shape, colorful in scheme, bright in color, and rounded across its corners.

25D-NBOMe’s geometry is reported to lead to level 8A visual geometry with experiences level 8B remaining so far unconfirmed within this substance. It also seems to consistently build up in visual intensity when the user stares at a central point. This eventually envelopes the visual field and creates the sensation that the user has broken through into a continuously shifting geometric landscape or structure with a vast sense of physical size attributed to it.

Hallucinatory states

25D-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently within doses higher than of 2mg. These effects include:

Auditory Effects

Sensory Effects

  • Dosage independent intensity - While the reasons for this are not understood, many reports suggest that this substance can produce unexpectedly strong or weak effects even when taken at the seemingly same dose in an unpredictable manner. This may contribute to the relative risk it is poses compared to most other psychedelics.
  • Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.

Transpersonal Effects

While they are occasionally reported, the transpersonal effects produced by this substance seem to be significantly less consistent and reproducible than other psychedelics, which perhaps corresponds with the mild alterations in the cognitive alterations it produces.

Legal Status


References

  1. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  2. 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  3. Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
  4. 25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  5. 25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  6. Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml
  7. Hansen, M. Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain. PhD Thesis, University of Copenhagen, 2011. | https://bitnest.netfirms.com/external.php?id=%18%3A3%172%1BE%24K%5BG%21%24%7D%04%04V
  8. Casale, John F.; Hays, Patrick A. (2012). "Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I" (PDF). Microgram Journal. 9 (2): 84–109. Retrieved 14 January 2014.
  9. Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMC 3963123 Freely accessible. PMID 24397362. https://doi.org/10.1021/cn400216u
  10. "Fatalities / Deaths". Erowid. April 26 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  11. http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml/
  12. https://erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  13. https://erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml
  14. https://erowid.org/chemicals/nbome/nbome_death.shtml
  15. https://onlinelibrary.wiley.com/doi/full/10.1002/dta.2751
  16. https://www.sciencedirect.com/science/article/abs/pii/S0033318218304882
  17. https://www.sciencedirect.com/science/article/abs/pii/S0378427418317533
  18. http://portal.anvisa.gov.br/documents/10181/3115436/(1)RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  19. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019.
  20. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
  21. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
  22. Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf
  23. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made
  24. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
  25. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28

Sources

Information made possible with:

  1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
  2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
  3. PubChem National Center for Bio Informatics
  4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
  5. Wikipedia

Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.

Data is constantly updated so please check back later to see if there is any more available information on this substance.